The skinny on earnings: Cost cuts boost Merck, Bristol-Myers, Forest as FX hits Sanofi
29.04.2014 / Fierce Pharma
While many drugmakers were marveling over Pfizer's big bid for AstraZeneca or speculating about which megadeal might come next, a few big pharma companies rolled out their first-quarter earnings reports. Let's give them their due. Besides, we can't be all deals, all the time. Here are the highlights–or, given the almost-uniform slide in sales, the lowlights.